Park Place Capital Corp Cuts Stock Position in Humana Inc. (NYSE:HUM)

Park Place Capital Corp lessened its holdings in Humana Inc. (NYSE:HUM) by 3.1% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 1,731 shares of the insurance provider’s stock after selling 55 shares during the period. Park Place Capital Corp’s holdings in Humana were worth $647,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Transcend Capital Advisors LLC bought a new position in shares of Humana in the 2nd quarter valued at about $433,000. Kathmere Capital Management LLC bought a new position in shares of Humana in the 2nd quarter valued at about $170,000. Clear Rock Advisors LLC lifted its stake in Humana by 4.0% in the first quarter. Clear Rock Advisors LLC now owns 5,131 shares of the insurance provider’s stock worth $1,779,000 after purchasing an additional 199 shares during the last quarter. Cetera Advisors LLC lifted its stake in Humana by 472.1% in the first quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider’s stock worth $3,501,000 after purchasing an additional 8,333 shares during the last quarter. Finally, Cetera Investment Advisers lifted its stake in Humana by 249.0% in the first quarter. Cetera Investment Advisers now owns 20,945 shares of the insurance provider’s stock worth $7,262,000 after purchasing an additional 14,944 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Up 1.3 %

HUM stock traded up $4.64 during trading on Friday, hitting $363.62. 1,076,306 shares of the company’s stock traded hands, compared to its average volume of 1,396,067. The firm has a market capitalization of $43.78 billion, a P/E ratio of 22.64, a PEG ratio of 2.09 and a beta of 0.51. The business has a fifty day simple moving average of $367.90 and a two-hundred day simple moving average of $347.35. The company has a quick ratio of 1.67, a current ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana Inc. has a 1 year low of $298.61 and a 1 year high of $530.54.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. During the same period in the previous year, the company earned $8.94 earnings per share. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. Sell-side analysts anticipate that Humana Inc. will post 16.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HUM shares. Baird R W raised shares of Humana to a “hold” rating in a research note on Thursday, May 30th. Royal Bank of Canada decreased their price objective on shares of Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. TD Cowen raised their price objective on shares of Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a research note on Friday. Finally, UBS Group decreased their price objective on shares of Humana from $334.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, April 25th. Fourteen research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $403.55.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.